KUMULUS-VAPE
28.5.2019 05:59:06 CEST | Business Wire | Press release
At 11.30 am this Tuesday, May 28 2019, shares in Kumulus Vape (ISIN: FR0013419876 - symbol: MLVAP) will be listed for the first time on the Euronext Access™ market in Paris (by technical admission). Kumulus Vape is an e-merchant specializing in the sale of electronic cigarettes and related 'vaping' products (equipment, e-liquids and accessories).
The listing on the Paris stock exchange is a first for European vape companies, marking a new milestone in the performance trajectory of the company from Lyon, a pioneer in its market in an active phase of development. The aim of this move is to enable Kumulus Vape to raise brand awareness and strengthen its presence on the domestic market.
55,000 shares will be offered for sale on the first day of market trading. This admission to the Euronext Access™ market constitutes a first step, prior to a possible transfer of Kumulus Vape shares to the Euronext Growth® market. The company seeks to introduce a dynamic of shares changing hands that could account for between 5 and 10% of the capital.
Established in 2012, Kumulus Vape is one of the main French online sites for the sale of vaping products (equipment, e-liquid, DIY1 ). With its broad range, comprising over 6,000 items, it offers products for both 'beginners' and vaping experts. As a committed player in combating tobacco and an advocate for the vaping sector, Kumulus Vape offers an unequalled choice of high-performing vaping products at low prices.
In 2018, Kumulus Vape's turnover was €6.5 million, up 116% on 2017. The EBITDA exceeded the €400,000 mark (+128% on 2017), with a net income of nearly €300,000 (+106%). In the first quarter of 2019, turnover rose by 96% to €2.3 million.
Kumulus Vape has a clear aim: to become one of the French leaders in 100% e-commerce vaping in the next three years.
Operating procedures
Listing market:
Euronext Access™
ISIN
:
FR0013419876
Symbol
: MLVAP
Registration procedure
:
technical admission
Number of shares in company capital
:
1,988,000
Number of shares sold on the day of listing
: 55,000
Sale
price per share
: €2.12
Valuation at time of listing
:
€4,214,560
Start of trading
: May 28, 2019
Eligible
for PEA (equity savings plan) and SME PEA
: yes
The operation does not require authorization from the French Financial Markets Authority (AMF). The information document has therefore not been approved by the AMF. The information document is available free of charge from the head office of Kumulus Vape. It may be downloaded from www.kumulusvape.fr/investisseurs . Please note that companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Instead, they are subject to a smaller set of rules that is suitable for small businesses experiencing growth. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company on the regulated market.
Partners in the operation
|
Atout Capital |
Consultant and listing sponsor |
|
|
Lamy Lexel |
Legal advice |
|
|
Mazars |
Auditors |
|
|
Actifin |
Financial communications |
|
About Kumulus Vape
Established in 2012, Kumulus Vape is one of the leading French distributors of e-cigarettes and e-liquids . With www.kumulusvape.fr , its website for individuals, and its wholesale business for specialist boutiques, the Company is positioned on both the B2C and B2B markets. Kumulus Vape's turnover rose to €6.5 million in 2018, representing a growth of 116% on 2017. Kumulus Vape is based in Corbas, just a few minutes from the south of Lyon, and currently has about 25 employees.
1 Do It Yourself: e-liquid base that people can use to create their own blends
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005309/en/
Contact:
KUMULUS VAPE Director of Communications Vincent Baudoin v.baudoin@kumulusvape.fr Tel.: 06 10 84 52 59
ACTIFIN Press relations Aminata Doucouré adoucoure@actifin.fr Tel.: 01 56 88 11 23
ACTIFIN Financial communications Julien Mouret jmouret@actifin.fr Tel.: 01 56 88 11 14
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 13:47:00 CEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 12:07:00 CEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX3.9.2026 12:05:00 CEST | Press release
Advancing AI Infrastructure Value Chain Through Integrated Power Management and Cooling Technologies LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. (“DCX Liquid Cooling Systems”), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI inf
The Untold Story ‘NEW YORK IN MONCLER’3.9.2026 12:00:00 CEST | Press release
A Retrospective of Pioneering New York Moments Some love stories take time. After decades of shared moments, Moncler reveals the story of its enduring relationship with New York through an expansive city-wide declaration of love. The untold story of New York in Moncler began when snow met concrete. What could have melted instead endured, forging a love built on pioneering moments and strengthened with every chapter. They found each other, again and again. Decades later, their story is finally ready to be shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903671495/en/ NEW YORK IN MONCLER MIDTOWN MOUNTAINS Revealed through one of the largest open-air public exhibitions the city has ever seen, New York in Monclerunveils the peak moments that capture the bond between New York and Moncler, transforming communal spaces across the city into a powerful retrospective gallery from September 9-13. New York in Moncleris a very p
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom